ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "proteomics"

  • Abstract Number: 0076 • ACR Convergence 2025

    Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis

    Emma Weis1, Harlan Sayles1, Geoffrey Thiele1, Samir Rachid Zaim2, Tony Merriman3, Bryant England1, Xiaojun Li2, LauraKay Moss4, Jess Edison5, Marie Feser4, V. Michael Holers6, Kevin Deane7, Ted Mikuls1 and Austin Wheeler1, 1University of Nebraska Medical Center, Omaha, NE, 2Allen Institute for Immunology, Seattle, WA, 3University of Alabama at Birmingham, Homewood, AL, 4University of Colorado Anschutz Medical Campus, Aurora, CO, 5Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD, 6University of Colorado, Denver, CO, 7University of Colorado Denver Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Circulating concentrations of anti-malondialdehyde-acetaldehyde (MAA) antibodies distinguish patients with RA and are detectable years prior to arthritis onset. Recent data demonstrate that anti-MAA antibodies…
  • Abstract Number: 2601 • ACR Convergence 2025

    Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity

    Antonios Psarras1, Sinibaldo Arocha2, Liezel Tamon2, David Ahern2, Md Yuzaiful Md Yusof3, Ed Vital4 and Alexander Clarke5, 1University of Oxford, Oxford, England, United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4University of Leeds, Leeds, England, United Kingdom, 5Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by innate immune activation and autoantibodies against nucleic self-antigens. The metabolic state of immune cells is emerging as…
  • Abstract Number: 0957 • ACR Convergence 2025

    Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc

    Astrid Hofman1, Pietro Bearzi2, Elena Pachera3, Cosimo Bruni4, Lumeng Li2, Laura Much5, Kristina Bürki1, Mike Becker6, Anna-Maria Hoffmann-Vold7 and Oliver Distler8, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4University of Zurich, Zurich, Switzerland, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 6Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 7Oslo University Hospital, Oslo, Norway, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Regression of skin fibrosis is a feature of the natural history of dcSSc. The molecular mechanisms underlying this resolution remain unclear. This study aims…
  • Abstract Number: 0071 • ACR Convergence 2025

    Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.

    Chary López pedrera1, Tomás Cerdó2, Ismael Sanchez-Pareja2, Daniel Toro3, MARIA ANGELES AGUIRRE ZAMORANO2, Elena Moreno-Caño4, Laura muñoz-Barrera2, Sagrario Corrales2, Rafaela Ortega-Castro5, Concepción Aranda-Valera6, Lourdes Ladehesa7, Jerusalén Calvo6, Pilar Font8, M Carmen Abalos-Aguilera9, Desiree Ruiz-Vilchez10, Christian Merlo-Ruiz9, Nuria Barbarroja11, Carlos Pérez Sánchez12, Marta Alarcon-Riquelme13 and Alejandro Escudero Contreras6, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 3GENYO / Karolinska Institutet, Granada / Stockholm, Spain, 4IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, 5Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 6IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 7IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 8Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 9Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 10Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 11Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 12Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 13Fundación Progreso y Salud, Andalusian Government, Granada, Spain

    Background/Purpose: This study aimed to identify shared and distinct gene and protein expression profiles associated with clinical features in rheumatoid arthritis (RA), systemic lupus erythematosus…
  • Abstract Number: 2509 • ACR Convergence 2025

    Predicting future relapse with proteomics in ANCA-Associated Vasculitis

    Evan Barnes1, Nora Shepherd2, Colebrooke Johnson1, David O'Dea1, Bohang Jiang3, Emily Hyle2, Zachary Williams4, Zachary Wallace5 and Gary Reynolds6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3MGH, Boston, MA, 4Massachusetts General Hospital, Nancy, KY, 5Massachusetts General Hospital, Newton, MA, 6Massachusetts General Hospital, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Outcomes for ANCA associated vasculitis (AAV) have been transformed in recent years with many patients achieving prolonged periods of remission. Guidelines advise continuing maintenance…
  • Abstract Number: 0919 • ACR Convergence 2025

    Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns

    Stefanie Kurth1, Andre Tiaden1, Edveena Hanser1, Simone Häner1, Stavros Giaglis1, Florian Geier1, Dominik Burri1, Katarzyna Buczak1, Ute Heider2, Stefan Wild2, Yves Acklin1, Christian Egloff1 and Diego Kyburz3, 1University of Basel, Basel, Switzerland, 2Miltenyi Biotec, Bergisch-Gladbach, Germany, 3University Hospital Basel, Basel, Switzerland

    Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of…
  • Abstract Number: 0070 • ACR Convergence 2025

    Integrating Synovial Protein Signatures and Serum Profiles to Predict Disease Activity and Treatment Response in Early Rheumatoid Arthritis

    Chary López pedrera1, Sagrario Corrales2, Julio Osuna3, Rafaela Ortega-Castro4, Jerusalén Calvo5, Lourdes Ladehesa6, Ismael Sanchez-Pareja2, Laura muñoz-Barrera2, Desiree Ruiz-Vilchez7, Christian Merlo8, MARIA ANGELES AGUIRRE ZAMORANO2, Nuria Barbarroja9, Tomás Cerdó2, Marta Alarcon-Riquelme10, Carlos Pérez Sánchez11, Alejandro Escudero Contreras5 and Concepción Aranda-Valera5, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Spain., Córdoba, Republic of Korea, 4Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 5IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 6IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 7Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 8Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 9Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 10Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 11Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: The analysis of synovial tissue has been instrumental in advancing our understanding of Rheumatoid Arthritis (RA) pathogenesis. As an alternative, the identification of serum…
  • Abstract Number: 2502 • ACR Convergence 2025

    Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study

    Santiago Dans Caballero1, Rafaela Ortega-Castro2, Chary López pedrera3, Alejandro Escudero4, Beatriz Vellón-García5, Carlos Pérez Sánchez6 and Clementina López Medina7, 1Reina Sofia University Hospital, Lebrija, Andalucia, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 4Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain, 5Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 7Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain

    Background/Purpose: Systemic sclerosis (SSc) is a clinically and biologically heterogeneous autoimmune disease characterized by multiorgan involvement, substantial morbidity, and high mortality. Traditional classification systems (based…
  • Abstract Number: 0873 • ACR Convergence 2025

    Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis

    Lihi Eder1, Shangzhong Li2, Philip J. Mease3, Christopher Ritchlin4, Walter P Maksymowych5, Hendrik Schulze-Koops6, Josef Smolen7, Oliver FitzGerald8, Vinod Chandran9, Chun Wu10 and Jinqi Liu2, 1University of Toronto, Toronto, ON, Canada, 2Bristol Myers Squibb, Princeton, NJ, 3Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 4University of Rochester Medical Center, Canandaigua, NY, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, 7Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 8UCD, Dublin 6, Dublin, Ireland, 9Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, 10Bristol Myers Squibb, Princeton

    Background/Purpose: PsA affects male and female patients equally; however, variations in manifestations and treatment response exist between sexes. Deucravacitinib is an oral, selective, allosteric tyrosine…
  • Abstract Number: 0048 • ACR Convergence 2025

    Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting

    Xue Wang1, Fei Wang2, Sílvia Sisó2, Archana Iyer2, Heather Knight2, Lori Duggan2, Yingli Yang2, Liang Jin2, Baoling Cui2, Yupeng He3, Jan Schejbal2, Lucy Phillips2, Bohdan Harvey4 and Yu Tian2, 1AbbVie, South San Francisco, CA, 2AbbVie, Worcester, MA, 3AbbVie, North Chicago, IL, 4AbbVie, Cambridge, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, fibroblast proliferation and progressive joint damage. Understanding the heterogeneity of RA and…
  • Abstract Number: 0888 • ACR Convergence 2024

    Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts

    Kevin Sheridan1, Emma Doris1, Maria Pimenta1, Jemma Falkov1, Matthew Fisher2, Munitta Muthana2, Denis Shields1, Richard Mains3, Betty Eipper3, Christopher Buckley4 and Anthony Wilson5, 1University College Dublin, Dublin, Ireland, 2University of Sheffield, Sheffield, United Kingdom, 3University of Connecticut, Connecticut, 4University of Oxford, Oxford, United Kingdom, 5UCD, Dublin, Dublin, Ireland

    Background/Purpose: The SNP rs26232 is associated with both risk and severity of rheumatoid arthritis (RA), with the C allele associated with the susceptibility to RA,…
  • Abstract Number: 1813 • ACR Convergence 2024

    Elucidating the Molecular Correlates of Treatment Response in Lupus Nephritis via Imaging Mass Cytometry Proteomics and Machine Learning

    Frank Sen Hee Tay1, Anto Sam Crosslee Louis Sam Titus2, Vinaika Maruvada2, Sandy Lim1, Jiacai Cho1, Thomas Thamboo1 and Chandra Mohan3, 1National University Hospital, Singapore, Singapore, 2University of Houston, Houston, 3University of Houston, Houston, TX

    Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE).  Despite the advances in the management…
  • Abstract Number: 0895 • ACR Convergence 2024

    Procoagulant Extracellular Vesicles in Patients with Livedo Reticularis

    Avital Baniel1, Cristina Ricco2, Rohan Dhiman3, Ahmed Eldaboush4, Caroline Stone4, Daniella Faden4, Luca Musante4, MIng-lin Liu4 and Victoria Werth5, 1Perelman School of Medicine, UPENN, Philadelphia, PA, 2university of pennsylvania, Philadelphia, 3University of Pennsylvania, Newport Coast, CA, 4University of pennsylvania, Philadelphia, PA, 5University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Procoagulant activity is an important property of EVs. Connective tissue disease (CTD) patients with livedo reticularis (LR) are known for their procoagulant conditions. The…
  • Abstract Number: 1825 • ACR Convergence 2024

    Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis

    Poulami Dey, Hiroshi Kato, Suiyuan Huang, Johann Gudjonsson, Dinesh Khanna, John Varga and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is marked by persistent fibrosis affecting both the skin and internal organs. Some regard SSc as a manifestation of expedited aging,…
  • Abstract Number: 0899 • ACR Convergence 2024

    Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis

    Ting-Shuan Wu1 and Yi-Ming Chen2, 1Chung Shan Medical University, Taichung, Taiwan (Republic of China), 2Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China)

    Background/Purpose: Rheumatoid arthritis (RA) is a common and complex inflammatory polyarthritis. Janus kinase inhibitors (JAKi) have shown superior efficacy compared to traditional treatments, but predictors…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology